Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home
NCT ID: NCT04922918
Last Updated: 2021-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
25 participants
INTERVENTIONAL
2020-10-01
2021-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly
NCT04756466
Modulation of Reproductive Microbiota by Ligilactobacillus Salivarius CECT5713
NCT06290518
Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.
NCT04165551
Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).
NCT04937556
Behavior of Various Galenic Forms of a Probiotic in the Digestive Tract.
NCT03143400
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic arm
Administration of Ligilactobacillus salivarius MP101 (\>9 log10cfu, daily) for 4 months
Ligilactobacillus salivarius MP101
Administration of the strain through a fermented milk
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ligilactobacillus salivarius MP101
Administration of the strain through a fermented milk
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent obtained
Exclusion Criteria
* Parenteral nutrition (exclusively)
* Allergy to cow's milk protein
74 Years
98 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Complutense de Madrid
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Juan M. Rodríguez
Head
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Para Mayores Santa Isabel, S.L.
Moralzarzal, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEIC 20/263-E_COVID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.